Calithera Biosciences, Inc. Overview
Pro stress-test →Calithera Biosciences operates under a plan of liquidation approved in January 2023 and was previously engaged in clinical stage precision oncology biopharmaceutical business. The company is winding up its operations and seeking to sell all of its clinical assets and programs.
Strategic Profile
Pro stress-test →The company was focused on discovery and development of small molecule inhibitors targeting metabolic pathways critical to cancer cell growth, aiming to create novel therapeutic options for solid tumors and hematologic malignancies. The company has not generated any revenue.
Competitive Landscape
Pro stress-test →Company is no longer a competitive participant in the oncology metabolic pathway inhibitor space. Historical competitors included other precision oncology firms developing tumor metabolism-targeting therapies, but Calithera has exited the competitive market through liquidation.
Industry Context
Calithera Biosciences, Inc. operates in Biopharmaceuticals (Liquidated/Shell Company Status).
Key facts
Founded: 2010 · Headquarters: South San Francisco, California · Revenue: $0 · Market cap: $974